autologous hematopoietic cell transplantation

PROCEDURE4 trials

Sponsors

Shanghai Jiao Tong University School of Medicine, Asan Medical Center, H. Lee Moffitt Cancer Center and Research Institute, Memorial Sloan Kettering Cancer Center

Conditions

Acute Promyelocytic LeukemiaLeukemia, MyeloidMultiple MyelomaRelapse

Early Phase 1

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

CompletedNCT02851056

H. Lee Moffitt Cancer Center and Research InstituteMultiple Myeloma

Start: 2016-09-27End: 2018-08-09Updated: 2022-11-14

Phase 2

ASCT for Relapsed APL After Molecular Remission

TerminatedNCT00907582

Shanghai Jiao Tong University School of MedicineAcute Promyelocytic Leukemia, Relapse

Start: 2009-06-30End: 2014-05-31Updated: 2014-12-02

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Active, not recruitingNCT03556332

Memorial Sloan Kettering Cancer CenterMultiple Myeloma

Start: 2018-07-02End: 2026-07-31Updated: 2025-04-29

Unknown Phase

Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia

CompletedNCT01050036

Asan Medical CenterLeukemia, Myeloid

Start: 2010-01-11End: 2018-10-30Updated: 2025-03-17

Related Papers

Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma

Clinical Cancer Research2023-09-2215 citations

Advances in Dendritic Cell-Based Therapies for Hematologic Malignancies

Oncology Times2020-04-10